Company intelligence / Profile preview
Opus Genetics
Durham, North Carolina, United States
- Ownership
- Public · IRD
- Employees
- ~18
- Development stage
- Phase 3
01
Overview
The most advanced program targets LCA5 mutations and has shown encouraging early data in a Phase 1/2 trial. Other AAV-based therapies are advancing toward clinical studies. Phentolamine Ophthalmic Solution 0.75% has reached Phase 3 for presbyopia and mesopic vision impairment post-surgery. APX3330 for non-proliferative diabetic retinopathy has FDA agreement on a Special Protocol Assessment for a pivotal trial.
- Therapeutic areas
- Ophthalmology
- Modalities
- Gene therapy (AAV-based)Small molecules
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Request access →03
Partnerships
Foundation Fighting Blindness’s venture arm—the Retinal Degeneration Fund—is a key backer/investor and strategic partner.No major pharma partnerships disclosed.
04
Financials
- Market cap
- $358.3M
- Total revenue
- $755K
- Enterprise value
- $304.5M
Beyond the preview
Go deeper on Opus Genetics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Opus Genetics.